A clinical trial update dated July 31, 2026 reports on a study titled Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists, registered as NCT07619989.
Tirzepatide is an approved incretin receptor agonist and is referenced in the context of this trial. The study status is listed as recruiting, and the trial phase is designated NA.
The trial is registered on ClinicalTrials.gov under the identifier NCT07619989. No results have been posted for this study at this time, and no outcome data are included in this update.
This brief reports only the status, phase, and title as listed in the trial record. No efficacy, safety, or comparative claims are made or implied by this update, and readers should not interpret the recruiting status as evidence of any particular result.
Further details on trial design, eligibility, and endpoints are available directly through the ClinicalTrials.gov listing. For general background on tirzepatide as a compound, readers can consult the compound overview for additional context.